Video information: Are there new developments in treating metastatic lung cancer? Dr. David Carbone of Ohio State University Comprehensive Cancer Center has much to report. From new medications that directly impact quality of life, rapid research to patients who are outliving their original prognosis, Dr. Carbone weighs in on...
Read More
Video information: At the 2017 ASCO meeting in Chicago, Dr. George Simon and Dr. David Carbone talk about news and progress in small cell lung cancer. Dr. Simon goes into detail on some new promising approaches and current studies for small cell lung cancer treatment, adding "these are some of the newer, in my opinion, more exciting approaches...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness of merestinib in non-small cell lung cancer patients with a mutation in the MET protein. The primary outcome will be measured by the overall response to the treatment. This study is being conducted in Boston, Massachusetts. The details Merestinib is an inhibitor of the C-Met...
Read More
In a nutshell This phase 2 clinical trial will test the safety and effectiveness of durvalumab as a first-line therapy for non-small cell lung cancer (NSCLC). The primary outcome will be measured by overall survival and the number of patients with adverse (negative) side effects. The details Durvalumab is an immunotherapy for metastatic tumors...
Read More
In a nutshell This phase 2 trial will clinical trial will test the effectiveness of lorlatinib in treating non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (ROS1) mutations. The primary outcome will be measured by the rate at which the disease spreads to the central nervous system (CNS). The...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness of poziotinib in treating locally advanced (spread to nearby tissue) or metastatic (spread to other parts of the body) non-small cell lung cancer (NSCLC) with an EGFR mutation. The primary outcome will be measured by the response rate to the treatment. This trial is being conducted...
Read More
In a nutshell This multicenter phase 3 clinical trial will test the effectiveness of nivolumab (Opdivo) after surgery and chemotherapy in stage 1b to 3a non-small cell lung cancer (NSCLC). The primary outcome will be measured by the length of time the patient survives without signs of the cancer and the overall survival rate for up to 10...
Read More
In a nutshell This phase 3 clinical trial will test the effectiveness of nivolumab (Opdivo), nivolumab with ipilimumab (Yervoy), or nivolumab with platinum-based chemotherapy compared with chemotherapy in treating patients with advanced non-small cell lung cancer (NSCLC). The primary outcome will be measured by the overall survival rate and time...
Read MoreIn a nutshell This meta-analysis aimed to establish the incidence of severe and fatal side effects associated with crizotinib (Xalkori) in patients with ALK-positive non-small-cell lung cancer (NSCLC). The authors concluded that crizotinib does not increase the risk of severe or fatal side effects compared to chemotherapy. Some background The...
Read More
In a nutshell This study examined the safety and effectiveness of durvalumab (Imfinzi) in patients with stage III non-small cell lung cancer. This study concluded that durvalumab delayed time to disease progression. Some background Chemotherapy and radiation are the standard treatment options for stage III non-small cell lung cancer (NSCLC, cancer...
Read More
From September 8 through 12th, over 24,000 oncologists and oncology researchers attended the European Society of Medical Oncology Meeting (ESMO), the equivalent of the American Society of Clinical Oncology Meeting (ASCO) held in the US. This year’s event focused on connecting researchers to practitioners in a meaningful way. Here are some research...
Read More
In a nutshell This study examined the use of a type of targeted therapy called immune checkpoint inhibitors to treat advanced non-small-cell lung cancer (NSCLC). The authors concluded that for patients who had a genetic mutation (change) called KRAS, ICIs were more effective than chemotherapy. They suggest that the presence of KRAS mutations could...
Read More
